Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
Formula 1 engine designers are wizards. They’re able to take F1’s incredibly complicated, highly restrictive rulebook and use it to create engines that are smaller than the Toyota Corolla’s but make 1 ...
The 2026 Formula 1 season features new rules, new cars and new opportunities as Lando Norris looks to fend off the chasing pack after winning his first driver's title last year. This year the grid ...
Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...
Effective duration estimates how much the price of a bond with embedded options will change when interest rates shift, focusing on duration as a tool for managing interest rate risk. Effective ...
Watch on as Oscar Piastri and Lando Norris propel McLaren’s ascendency to the pinnacle of F1 Witness the Brackley based Silver Arrows travel the world, as one of the most successful teams in the sport ...
Find out the direct holders, institutional holders and mutual fund holders for Recursion Pharmaceuticals, Inc. (RXRX).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results